Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

The George Institute: Clinical Trials & FDA Approval Profile

The George Institute (Global / Institutional) sponsors 15 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 8 active protocols (7 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)20.0%
Median Closed Enrollment vs National (145 pts)190 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for The George Institute
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)15
Active Pipeline (Recruiting Now)8 (7)
Completed vs Stopped Early4 / 3 (20.0%)
Median Closed Actual Enrollment190 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With The George Institute
Hospital Research SiteLocationShared Protocols
Westmead HospitalWestmead, New South Wales4
Austin HealthHeidelberg, Victoria3
Royal North Shore HospitalSt Leonards, New South Wales3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by The George Institute
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06409364FLudrocortisone Administration in Aneurysmal Subarachnoid HaemorrhagePhase IIRECRUITING
NCT06058585The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the The George Institute Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI